REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options, RSUs and PSUs and PDMR Dealing
24/03/2025 09:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250324:nRSX8654Ba&default-theme=true
RNS Number : 8654B MaxCyte, Inc. 24 March 2025
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options, RSUs and PSUs and PDMR Dealing
Rockville, Maryland - 24 March 2025: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and commercialization of
next-generation cell-based therapeutics, announces that on 14 March 2025, a
grant of 347,500 stock options in respect to common stock of the Company, and
a target grant of 347,500 performance stock units ("PSUs") were granted to
Maher Masoud, President, Chief Executive Officer and Director of the Company,
and 150,000 options in respect of common stock in the Company, 37,500
restricted stock units ("RSUs") and a target grant of 37,500 PSUs were granted
to Douglas Swirsky, Chief Financial Officer of the Company.
Details of the stock options
The options granted to Messers. Masoud and Swirsky vest as to 25% of the total
grant on the first anniversary of the date of grant, and the remaining 75%
vest in 36 equal monthly instalments thereafter.
The options granted to Messers. Masoud and Swirsky have an exercise period of
10 years from date of grant, at which time they will expire, and have an
exercise price of $3.29, being equal to the closing price of MaxCyte's common
stock on Nasdaq on 14 March 2025.
Details of the RSUs
Each RSU represents the contingent right to receive one share of common stock
in the Company. The RSUs granted to Mr. Swirsky vest as to 25% on each of the
first, second, third and fourth anniversary of the date of grant. No exercise
price is payable on vesting or settlement of the RSUs.
Details of the PSUs
Each PSU represents the contingent right to receive one share of common stock
in the Company upon the achievement of specified performance metrics. The PSU
grants made to Messrs. Masoud and Swirsky on 14 March 2025 represent a number
of shares of common stock to be earned if the target level of performance is
achieved. The performance period continues through 31 December 2027, after
which time the level of performance achievement will be determined by the
Board of Directors or an authorized committee thereof. The actual number of
shares of common stock underlying the PSUs to be earned will be between 0% and
125% of the target number of PSUs, depending on the level of achievement of
such performance metrics. No exercise price is payable on the vesting or
settlement of the PSUs.
The information in the tables below is provided in accordance with the
requirements of the UK Market Abuse Regulation.
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to support
innovative, cell-based research. Over the past 20 years, we have developed and
commercialized our proprietary Flow Electroporation® technology, which
facilitates complex engineering of a wide variety of cells. Our ExPERT™
platform, which is based on our Flow Electroporation technology, has been
designed to support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of next-generation,
cell-based medicines. The ExPERT family of products includes: four
instruments, the ATx®, STx® GTx® and VLx™; a portfolio of proprietary
related processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio. Learn more
at maxcyte.com (https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/MaxCyte_info) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group +1 415-937-5400
David Deuchler, CFA ir@maxcyte.com (mailto:ir@maxcyte.com)
Nominated Adviser and Joint Corporate Broker
Panmure Liberum +44 (0)20 7886 2500
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser +44 (0)203 709 5700
ICR Healthcre maxcyte@icrhealthcare.com (mailto:maxcyte@icrhealthcare.com)
Mary-Jane Elliott
Chris Welsh
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com and follow us on X and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Maher Masoud
2 Reason for the notification
a) Position/status President, CEO and Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Grant of options and PSUs in respect of common stock
c) Price(s) and volume(s) Options:
Exercise Price(s) Volume(s)
$3.29 347,500
PSUs:
Exercise Price(s) Volume(s)
N/A 347,500
d) Aggregated information
- Aggregated volume 347,500 options and 347,500 PSUs (up to 781,875 shares of common stock if
performance metrics for the PSUs are fully satisfied)
- Price $3.29 for the options; no exercise price for the PSUs
e) Date of the transaction 14 March, 2025
f) Place of the transaction US Stock Exchange, Nasdaq
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Douglas Swirsky
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name MaxCyte Inc.
b) LEI 54930053YHXULRFCU991
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common stock of $0.01 each
Identification code US57777K1060
b) Nature of the transaction Grant of options, RSUs and PSUs in respect of common stock
c) Price(s) and volume(s) Options:
Exercise Price(s) Volume(s)
$3.29 150,000
RSUs:
Exercise Price(s) Volume(s)
N/A 37,500
PSUs:
Exercise Price(s) Volume(s)
N/A 37,500
d) Aggregated information
- Aggregated volume 150,000 options, 37,500 RSUs and 37,500 PSUs (up to 234,375 shares of common
stock if performance metrics for the PSUs are fully satisfied)
- Price $3.29 for the options; no exercise price for the RSUs and PSUs
e) Date of the transaction 14 March, 2025
f) Place of the transaction US Stock Exchange, Nasdaq
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUSRKRVUUOURRRecent news on MaxCyte
See all newsREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Total Voting Rights
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Filing of definitive proxy statement
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
AnnouncementREG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Announcement